62 results about "Benzyl benzoat" patented technology

The invention relates to the technical field of rubber material preparation, and discloses an environment-friendly sponge and application thereof.The environment-friendly sponge is prepared from, by weight, 110-150 parts of polyether polyol, 60-80 parts of diphenylmethane diisocyanate, 2-8 parts of a cross-linking agent, 5-10 parts of an opening agent, 3-5 parts of a foaming agent, 0.1-0.5 part of a foam stabilizer, 1.5-2.5 parts of an amine catalyst, 5-10 parts of antibacterial microcapsules and 10-15 parts of modified hybrid nanoparticles; the antibacterial microcapsule is a polyurea microcapsule which is prepared by adopting an interfacial polymerization method and contains benzyl benzoate and 1, 2-benzisothiazole-3-ketone, the modified hybrid nanoparticle is a nano titanium dioxide-nano zinc oxide hybrid particle grafted triazine derivative, and the triazine derivative molecule contains a hindered phenol structure and a siloxane structure. The antibacterial microcapsules are added into the polyurethane foam sponge, the mite killing effect and antibacterial property of the environment-friendly sponge are effectively improved, and meanwhile, the modified hybrid nanoparticles are added, so that the aging resistance of the environment-friendly sponge is improved.

To provide a mite repellent composition having an excellent mite repellent effect against house dust mites even after a long time has elapsed and also having excellent safety for humans and animals.SOLUTION: A mite repellent composition contains: (a) 1,8-cineol and / or 1,4-cineol; and (b) a perfume component, wherein the perfume component includes one or more kinds of perfume compounds having a logP value of 2.0 to 5.5. A blending ratio (a / b) of the component (a) to the perfume compound contained in component (b) is set to 5 to 100 on a mass basis. The perfume compound contained in the component (b) is at least one selected from the group consisting of ethyl cinnamate, allyl caproate, 3-methyl-5-phenyl-1-pentanol, citronellol, δ-dodecalactone, β-ionone, benzyl benzoate, linalyl acetate, geranyl acetate, tricyclodecenyl propionate, benzyl salicylate, limonene, and amyl salicylate.SELECTED DRAWING: None

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition containing Bremelinodan, a preparation as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition provided by the invention comprises a pharmaceutical active ingredient Bramer nodan, a solvent and a polymer, and the solvent comprises one or more of N-methyl pyrrolidone, polyethylene glycol, dimethyl sulfoxide and benzyl benzoate. According to the pharmaceutical composition containing the Bramer captan, the blood concentration of the Bramer captan is stably larger than 0.1 ng / mL within 120-168 h, target slow release is achieved, direct injection can be achieved, liquid medicine does not need to be mixed before use, the preparation process is simple, the component is single, a thickening agent, a gel forming agent or other auxiliary materials do not need to be added, large-scale production can be achieved, cost is low, and the pharmaceutical composition is suitable for industrial production. Good market application prospects are realized.

The present invention addresses the problem of improving the change in smell of stearyl glycyrrhetinate,. This composition is characterized by containing components (A)–(C). (A) Stearyl glycyrrhetinate, (B) niacinamide or tranexamic acid, and (C) at least one compound selected from the group that consists of anisyl alcohol, farnesol, eugenol, citronellol, α-pinene, 1-hexanol (hexen-1-ol), linalool, cedryl acetate, Iso E Super, Sandalore, Ambroxan, γ-terpinene, ambrettolide, β-ionone, borneol, isobutyl quinoline, citral, guaiacol, patchouli alcohol, cedrol, ethyl vanillin, maltol, linalyl acetate, α-terpineol, benzyl benzoate, damascenone, anisaldehyde, benzaldehyde, Magnolan, Mayol, phenylacetaldehyde dimethyl acetal, nerol, dimethyl benzyl carbinol, Bacdanol, methyl anthranilate, Muscenone, benzyl acetate, phenylethyl alcohol, phenylethyl acetate, and heliotropine.

Provided is an aggregate amount regulator having an excellent aggregate production promoting effect. Use of a compound selected from the group consisting of 4-ethyl-alpha, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta, beta The compound is at least one compound selected from the group consisting of alpha, alpha-dimethyl benzene propionaldehyde, 1-(2-tert-butylcyclohexyloxy)-2-butanol, benzyl benzoate, tricyclodecenyl acetate, trichloromethyl phenyl methyl acetate, geraniol, cyclohexylidene (phenyl) acetonitrile, 1-menthol, linacol, dihydromyrcenol, benzyl salicylate, 4-(5, 5, 6-trimethylbicyclo [2.2. 1] heptane-2-yl) cyclohexanol, and the like.

Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.

A bremelanotide pharmaceutical composition, a formulation thereof, a preparation method therefor, and use thereof. The bremelanotide pharmaceutical composition comprises bremelanotide as a pharmaceutically active ingredient, a solvent, and a polymer. The solvent includes one or more of N-methylpyrrolidone, polyethylene glycol, dimethyl sulfoxide, and benzyl benzoate and enables the plasma concentration of bremelanotide to be stably greater than 0.1 ng / mL at 120-168 h, thereby achieving the target sustained release. The bremelanotide pharmaceutical composition can be directly injected and does not require the addition of a thickener, a gel-forming agent, or other excipients.

The present invention provides a repellent composition for mites which is excellent in mite-repelling effect against indoor mites even after a long period of time and is also excellent in safety to humans and animals. The present invention relates to a repellent composition for mites, which contains: (a) 1,8-cineol and / or 1,4-cineol and (b) a perfume ingredient, wherein the perfume ingredient contains one or two or more kinds of perfume compounds having a logP value of 2.0 to 5.5. The mixing ratio (a) / (b) of the (a) ingredient to the perfume compounds contained in the (b) ingredient is set to 5 to 100 on a mass basis. The perfume compounds contained in the (b) ingredient are at least one selected from the group consisting of ethyl cinnamate, allyl caproate, 3-methyl-5-phenyl-1-pentanol, citronellol, δ-dodecalactone, β-ionone, benzyl benzoate, linalyl acetate, geranyl acetate, tricyclo decenyl propionate, benzyl salicylate, limonene, and amyl salicylate.

The invention relates to the technical field of flavors and fragrances, in particular to a green tea extract-containing flavors and fragrances and a preparation method thereof. The essence and perfume is prepared from the following raw materials in percentage by mass: 83.1 to 94.6 percent of propylene glycol, 0.8 to 2.5 percent of linalool oxide, 0.5 to 1.5 percent of linalool, 1 to 1.8 percent of phenethyl alcohol, 0.4 to 1 percent of eugenol, 0.1 to 0.6 percent of cis-jasmonone, 0.7 to 2.5 percent of methyl dihydrojasmonate, 1 to 3 percent of benzyl benzoate, 0.6 to 2.5 percent of methyl jasmonate and 0.3 to 1.5 percent of green tea extract; therefore, the essence perfume containing the green tea extract is obtained. Wherein the green tea extract is subjected to fractional extraction and synergistic fermentation of an enzyme preparation, various strains and a composite additive in a specific mass ratio, so that the extraction efficiency is improved, and the tea aroma and the flower and fruit aroma of the product are enhanced.

The present invention provides novel compositions for treating malarial infections comprising prodrugs of ELQ-300 and an oil, wherein the composition can further comprise benzyl alcohol and / or benzyl benzoate, and methods of use thereof.

Kosmetische Zubereitung enthaltend 4-Hydroxy-3-methoxybenzaldehyd (INCI: Vanillin), 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin (INCI: Bis- Ethylhexyloxyphenol methoxyphenyl Triazine), Dipropylenglycoldibenzoat (INCI: Dipropylene Glycol Dibenzoate) und Benzylbenzoat (INCI: Benzyl Benzoate).

The invention belongs to the technical field of plant genetic engineering, and discloses a coding gene of benzyl benzoate 2-hydroxylase participating in a rice PAL-dependent salicylic acid synthesis pathway and application of the coding gene, and the nucleotide sequence of OSD3 is SEQ ID NO: 1; the nucleotide sequence of a coding protein region is SEQ ID NO: 2; the amino acid sequence of the coded protein is SEQ ID NO: 3; according to the invention, an OSD3 gene is knocked out through CRISPR / Cas9 under the background of Zhonghua 11, a mutant osd3 of which the SA of a rice leaf is reduced to 20% of that of a wild type is obtained, and an OSD3 overexpression plant is created by constructing an OSD3-pMDC43 overexpression vector.

The invention belongs to the technical field of plant genetic engineering, and discloses a gene for regulating and controlling the endogenous salicylic acid content and disease resistance of rice by using an SA synthetic gene OSD3 participating in rice PAL dependence and application of the gene, and the nucleotide sequence of the OSD3 is SEQ ID NO: 1; the nucleotide sequence of a coding protein region is SEQ ID NO: 2; the amino acid sequence of the coded protein is SEQ ID NO: 3; according to the invention, an OSD3 gene is knocked out through CRISPR / Cas9 under the background of Zhonghua 11, a mutant osd3 of which the SA of a rice leaf is reduced to 20% of that of a wild type is obtained, and an OSD3 overexpression plant is created by constructing an OSD3-pMDC43 overexpression vector.

The invention relates to the field of dielectric oil, in particular to a composition with benzyl benzoate and benzyl toluene as main components and application of the composition. The composition comprises benzyl benzoate and benzyl toluene, and is formed by compounding and refining benzyl benzoate and benzyl toluene as main components, the comprehensive performance of the composition is excellent and is not inferior to that of existing like products, and particularly, the dielectric constant is obviously improved.

An injectable pharmaceutical composition comprising a solution of 3-acyl-buprenorphine or a pharmaceutical salt thereof in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a sustained release profile lasting for more than one week when injected into a patient. The acyl group is an alkylcarbonyl group and an alkyl portion of the alkylcarbonyl group is straight chain, branched chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, isopropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.

This invention belongs to the field of polyether polyol synthesis technology, specifically relating to bio-based high-strength polyether ester polyols and their preparation methods. The bio-based high-strength polyether ester polyol is obtained from the following raw materials: small molecule polyol, catalyst, bio-based epoxide, and bio-based phenyl ester compound; the bio-based epoxide is one or more of limonene epoxide, α-pinene oxide, and caryophyllene oxide; the bio-based phenyl ester compound is one or two of benzyl benzoate and benzyl cinnamate. The raw materials used in this invention can be obtained through natural plant extraction, achieving full bio-based polyether ester polyol production, thus fundamentally reducing dependence on fossil resources. By introducing a large number of cyclic and benzene ring structures into the polyol molecule, the resulting product is applied in the field of rigid polyurethane foam, increasing the content of rigid groups in the molecular chain structure, and significantly improving the strength of rigid polyurethane foam compared to traditional polyether polyols.

This invention discloses the application of benzyl benzoate in the preparation of repellents for red imported fire ants. Experiments verified that after treatment with benzyl benzoate at a concentration of 1 μL / mL or higher for 0.5 h, the feeding and repellency rate of red imported fire ant workers reached 92.74%. After 12 h of treatment, benzyl benzoate at a concentration of 10 μL / mL or higher still maintained a good repellent effect, indicating that benzyl benzoate has a long-lasting repellent activity against red imported fire ants. After treatment with benzyl benzoate at a concentration of 50 μL / mL or higher for 24 h, the burrowing behavior of red imported fire ant workers was significantly reduced. Benzyl benzoate at a concentration of 10 μL / mL or higher showed good repellent effects against red imported fire ants and can be used in future red imported fire ant protective agents; benzyl benzoate at a concentration of 50 μL / mL or higher can be used in red imported fire ant soil repellents.

The invention belongs to the technical field of polyether polyol synthesis, and particularly relates to bio-based high-strength polyether ester polyol and a preparation method thereof. The bio-based high-strength polyether ester polyol is prepared from the following raw materials: micromolecular polyol, a catalyst, a bio-based epoxide and a bio-based phenyl ester compound, the bio-based epoxide is one or more of limonene epoxide, alpha-pinene oxide and caryophyllene oxide; the bio-based phenyl ester compound is one or two of benzyl benzoate and benzyl cinnamate. The raw materials can be extracted from natural plants, full bio-based polyether ester polyol is realized, dependence on fossil resources is more thoroughly reduced from the source, a large number of cyclic and benzene ring structures are introduced into polyol molecules, and the obtained product is applied to the field of rigid polyurethane foam plastics and has a wide application prospect. The content of rigid groups in a molecular chain structure is increased, and compared with traditional polyether polyol, the strength of rigid polyurethane foam can be greatly improved.

This invention relates to the field of progesterone preparation technology, specifically to a progesterone lipid liquid crystal suitable for injection, its preparation method, and the pharmaceutical uses of the product. The progesterone lipid liquid crystal injection provided by this invention is a lipid liquid crystal system formed by mixing an oil phase and an aqueous phase. The oil phase includes progesterone, benzyl benzoate, phospholipids, vitamin E, and oleic acid, while the aqueous phase includes water for injection. This invention optimizes the mass ratio of phospholipids to oleic acid in the oil phase to 10:1, and the mass ratio of progesterone, benzyl benzoate, and vitamin E to 2:6:(5-3), resulting in a stable lipid liquid crystal system that improves injection compliance, reduces fat deposition, and achieves sustained drug efficacy for more than 12 hours.

The utility model relates to the technical field of sewage treatment, in particular to a benzyl benzoate static crystallization and purification device which comprises a container, the container is provided with a feed port and a discharge port, and at least three heat exchange pipelines are arranged in the container; the heat exchange pipeline comprises an inner pipe and an outer pipe, the outer pipe sleeves the outer side of the inner pipe, and the inner pipe and the outer pipe are coaxial; the outer wall of the inner pipe is thinner than the inner wall of the outer pipe, so that a gap is formed between the inner pipe and the outer pipe, the two ends of the gap are sealed, and water is contained in the gap; an inlet and an outlet of the inner pipe extend out of the container; an outlet of the inner pipe is communicated with the liquid storage tank; the device further comprises a switching valve. An outlet of the switching valve is connected to a liquid supply pipeline; the liquid supply pipeline is connected to at least three liquid supply branch pipes; the at least three liquid supply branch pipes are respectively communicated with inlets of inner pipes of the at least three heat exchange pipelines; two liquid inlets of the switching valve are respectively communicated with a cold liquid supply pipeline and a hot liquid supply pipeline; benzyl benzoate crystallization is more uniform, and purity and yield of benzyl benzoate crystallization purification are improved.

The present invention provides an environmentally friendly dewaxing transparent reagent and its preparation method and application, the environmentally friendly dewaxing transparent reagent includes an initiator, a wax dissolving agent, a transparent agent and a solution modifier; the initiator includes normal paraffin; the wax dissolving agent includes isoparaffin; the transparent agent includes any one or a combination of at least two of tert-butyl alcohol, PEG methacrylate, N,N,N,N-tetrakis (2-hydroxypropyl) ethylenediamine, benzyl benzoate, polyethylene glycol, benzyl alcohol or diphenyl ether. The environmentally friendly dewaxing transparent reagent is used for film-making process, the environmentally friendly dewaxing transparent reagent has stable wax dissolving, fast wax dissolving speed, low volatility, low odor, high ignition point, and the dewaxing transparent reagent can reduce the tissue refractive index, so that the slice is more uniform and transparent, and the slice structure is clear. The raw material of the dewaxing transparent reagent is a non-toxic and safe product, which is safe and convenient to use.

The invention discloses application of benzyl benzoate in preparation of a red imported fire ant repellent. Experiments prove that the feeding repellent rate of the red imported fire ant worker ant reaches 92.74% after the red imported fire ant worker ant is treated by benzyl benzoate with the concentration of more than 1 microliter / mL for 0.5 h; after treatment for 12 h, benzyl benzoate with the concentration of 10 microliters / mL or above still keeps a good repelling effect, and it is indicated that benzyl benzoate has lasting repelling activity on solenopsis invicta. And after being treated by benzyl benzoate with the concentration of more than 50 microliters per milliliter for 24 hours, the digging habit of the red imported fire ant worker ant can be obviously reduced. Benzyl benzoate with the concentration of 10 microliters / mL or above has a good repelling effect on solenopsis invicta and can be used as a solenopsis invicta protection agent in the future; benzyl benzoate with the concentration of more than 50 microliters per milliliter can be used for red imported fire ant soil repellents.

The invention discloses a progesterone long-acting slow-release injection as well as a preparation method and medical application thereof. The progesterone long-acting slow-release injection comprises a therapeutically effective amount of progesterone, a pharmaceutically acceptable ester organic solvent; the solvent is selected from the combination of glyceryl triacetate and benzyl benzoate. The progesterone long-acting slow-release injection provided by the invention can form a drug reservoir in situ after injection, realizes long-term slow release of progesterone, remarkably reduces the initial burst release effect, and can be used for treating or preventing luteal insufficiency or luteal support in assisted reproduction. In addition, the progesterone long-acting slow-release injection is simple in preparation process, all the components can be dissolved and mixed at the room temperature, and large-scale production is easy to achieve.

The application provides a dibenzyl ether oxidation process, which utilizes oxygen to react with dibenzyl ether, compared with the traditional oxidation process using nitric acid or air as an oxidant, tail gas generation and treatment are avoided, VOC emission in the tail gas is avoided, and environmental pollution is reduced; the dibenzyl ether oxidation process can obtain benzaldehyde and benzyl benzoate simultaneously by using the by-product dibenzyl ether in industry, the process is simple, and economic benefits are high; the reactor of the dibenzyl ether oxidation process is a micro-channel reactor, by controlling the reaction temperature in the reactor to be 160-180 DEG C, the reaction pressure to be 1.5-2.5 Mpa, and the reaction time to be 5-10 min, oxygen and dibenzyl ether can be fully contacted and mixed, the oxidation rate is greatly improved, meanwhile, the residence time of the material in the reactor is short, the volume and liquid holding capacity of the reactor are relatively small, so that the investment cost and danger of the process are small.

Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

The invention provides functional aromatherapy essential oil and a preparation device thereof, the functional aromatherapy essential oil comprises a neurotransmitter regulation and control group, a meridian stimulation group and a biological rhythm regulation group, the neurotransmitter regulation and control group comprises 5-15 parts of lavender essential oil and 3-10 parts of Roman chamomile essential oil; according to the invention, a composite system of a neurotransmitter regulation group, a meridian stimulation group and a biological rhythm regulation group is adopted, and all the components form a multi-target synergistic effect through a specific ratio; according to the supercritical CO2 extraction technology of ligusticum wallichii, it is ensured that the ligustilide content is larger than or equal to 8%; the evening primrose seed oil is encapsulated by a beta-cyclodextrin embedding technology, so that gamma-linolenic acid is effectively prevented from being oxidized, and the shelf life of the product is prolonged; according to the formula, transmission of neurotransmitters is regulated and controlled through linalyl acetate and alpha-bisabolol, meridian circulation is stimulated by means of d-limonene, the secretion period of human melatonin is synchronized through benzyl benzoate, three-dimensional adjustment of nerves, meridians and rhythms is achieved, and the limitation of traditional single-target action is broken through.

The invention provides a progesterone slow-release oily injection. The progesterone slow-release oily injection comprises 6-30 wt% of progesterone; 5-80 wt% of an organic solvent; and, optionally, 10 to 70 wt% of oil for injection; the organic solvent comprises at least one of benzyl benzoate or benzyl alcohol. The injection provided by the invention can be used for treating threatened abortion, assisting reproduction or regulating and controlling the reproduction cycle, and has the characteristics of long-acting slow release, low injection frequency, good safety, simple preparation method, easiness in expanded production and the like.

Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.

The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a zolpidem tartrate orally disintegrating sustained-release tablet and a preparation method thereof. The sustained-release tablet comprises zolpidem tartrate, a sustained-release material, benzyl benzoate or / and methyl cyclodextrin, a filler, a disintegrant, a colorant and a lubricant. The tablet has a certain sustained-release effect on the basis of maintaining rapid disintegration characteristics, does not cause drowsiness the next day, has good stability, and has a simple preparation process, and is suitable for commercial production.

The invention relates to the technical field of benzyl benzoate preparation, and discloses a separation and purification method of benzyl benzoate as a byproduct of a process for preparing benzoic acid through toluene oxidation, the separation and purification method comprises distillation, rectification and melt crystallization, and the melt crystallization comprises primary crystallization and secondary crystallization. According to the scheme, kettle residues and tar in benzyl benzoate are removed through distillation, benzyl benzoate with the raw material external standard content of about 46% is purified to about 72%, the product content is increased to about 92% through rectification, and then the content is increased to 99% through primary crystallization, so that the purity of benzyl benzoate is improved. And finally, 99% of the product is subjected to secondary crystallization to obtain a perfume-grade product with the content being greater than or equal to 99.9% and the chromaticity being less than or equal to 20 (platinum cobalt), and the method has very high popularization and application value in the industry.